Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Affymax Inc (AFFY)  
$0.00 0.00 (0.00%) as of 4:30 Tue 4/23


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 37,490,000
Market Cap: 26.24(K)
Last Volume: 125 Avg Vol: 35,949
52 Week Range: $0.0002 - $0.0044
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    NASDAQ COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Affymax is a biopharmaceutical company in the process of restructuring operations. Co.'s U.S. Food and Drug Administration approved product, OMONTYS® (peginesatide) Injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis, has been recalled. As a result of the voluntary recall of OMONTYS, all marketing activities were suspended and sales were ceased. Co. granted its collaboration partner, Takeda Pharmaceutical Company Limited, a license to OMONTYS.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 0 0 0 0
Total Sell Value $0 $0 $0 $0
Total People Sold 0 0 0 0
Total Sell Transactions 0 0 0 0
End Date 2024-02-04 2023-11-03 2023-05-05 2022-05-05

   
Records found: 225
  Page 4 of 9  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Orwin John A CEO   •       •      –    2012-08-01 4 OE $5.83 $6,413 D/D 1,100 93,100     -
   Cross Herb Chief Financial Officer   •       –      –    2012-07-17 4 AS $17.00 $170,000 D/D (10,000) 10,000     -
   Cross Herb Chief Financial Officer   •       –      –    2012-07-17 4 OE $6.23 $62,300 D/D 10,000 20,000     -
   Knapp Jeffrey H Chief Commercial Officer   •       –      –    2012-07-16 4 AS $16.29 $74,681 D/D (4,584) 22,428     -
   Knapp Jeffrey H Chief Commercial Officer   •       –      –    2012-07-16 4 OE $6.23 $36,098 D/D 4,584 27,012     -
   Orwin John A CEO   •       •      –    2012-07-13 4 AS $15.00 $280,500 D/D (18,700) 92,000     -
   Orwin John A CEO   •       •      –    2012-07-13 4 OE $5.83 $12,826 D/D 2,200 110,700     -
   Knapp Jeffrey H Chief Commercial Officer   •       –      –    2012-07-13 4 AS $15.00 $84,975 D/D (5,665) 22,428     -
   Knapp Jeffrey H Chief Commercial Officer   •       –      –    2012-07-13 4 OE $10.99 $52,224 D/D 4,752 28,093     -
   Cross Herb Chief Financial Officer   •       –      –    2012-07-13 4 AS $15.50 $232,500 D/D (15,000) 10,000     -
   Cross Herb Chief Financial Officer   •       –      –    2012-07-13 4 OE $5.10 $76,500 D/D 15,000 25,000     -
   Knapp Jeffrey H Chief Commercial Officer   •       –      –    2012-06-15 4 AS $13.10 $39,300 D/D (3,000) 23,341     -
   Knapp Jeffrey H Chief Commercial Officer   •       –      –    2012-06-15 4 OE $6.23 $18,690 D/D 3,000 26,341     -
   Duliege Anne-Marie Chief Medical Officer   •       –      –    2012-05-25 4 AS $14.11 $52,052 D/D (3,689) 32,829     -
   Knapp Jeffrey H Chief Commercial Officer   •       –      –    2012-05-15 4 AS $14.27 $42,824 D/D (3,000) 23,341     -
   Knapp Jeffrey H Chief Commercial Officer   •       –      –    2012-05-15 4 OE $6.23 $18,690 D/D 3,000 26,341     -
   Venteicher Robert SVP, Technical Operations   •       –      –    2012-04-27 4 S $13.23 $72,420 D/D (5,474) 24,994     -
   Orwin John A CEO   •       •      –    2012-04-27 4 AS $13.35 $400,608 D/D (30,000) 108,500     -
   Knapp Jeffrey H Chief Commercial Officer   •       –      –    2012-04-24 4 AS $12.50 $30,175 D/D (2,414) 23,341     -
   Knapp Jeffrey H Chief Commercial Officer   •       –      –    2012-04-24 4 OE $6.23 $9,345 D/D 1,500 25,755     -
   Knapp Jeffrey H Chief Commercial Officer   •       –      –    2012-04-16 4 AS $11.86 $28,630 D/D (2,414) 24,255     -
   Knapp Jeffrey H Chief Commercial Officer   •       –      –    2012-04-16 4 OE $6.23 $9,345 D/D 1,500 26,669     -
   Orwin John A CEO   •       •      –    2012-04-03 4 AS $11.93 $196,845 D/D (16,500) 138,500     -
   Knapp Jeffrey H Chief Commercial OfficerOffice   •       –      –    2012-03-27 3 IO $0.00 $0 D/D 0 25,169     -
   Orwin John A CEO   •       •      –    2012-03-27 4 AS $15.70 $128,740 D/D (8,200) 155,000     -
  225 Records found
  1  2  3  4  5  6  7  8  9   
  Page 4 of 9
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us